ZLJT may inhibit LUAD cell EGFR-TKIs resistance by altering signal transduction pathways, blocking the tumor cell cycle, suppressing tumor activity, enhancing cell vitality, and improving the bioavailability of coadministered drugs. The gene discussed is EGFR; the disease is neoplasm.